Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 23, 2011

View Archived Issues

KAI Pharmaceuticals releases clinical data on KAI-4169

Bendamustine evaluated in anaplastic glioma

Promising preclinical data presented on GBR-401

Potential new biomarker for the diagnosis of giant cell arteritis

Plasma biomarker of small cell lung cancer identified

DNA polymerase eta levels predict oxaliplatin efficacy in esophageal cancer

Bafetinib as potential therapeutic for Parkinson's disease

Merck & Co. designs novel beta3-adrenoceptor agonists

New lysophospholipid S1P1 receptor modulators disclosed by Allergan

Phase III study of DiaPep277 in type 1 diabetes meets primary endpoint

Selecta Biosciences commences clinical trial of vaccine for smoking cessation

New steroidal lactones from M. crassissima disclosed by PharmaMar

Portola completes financing round

Pierre Fabre Medicament gains approval to market Joncia in Australia

Pfizer to acquire Excaliard Pharmaceuticals

Japanese researchers prepare novel Toll-like receptor antagonists

Compounds that modulate skeletal muscle contractility disclosed by Cytokinetics

Cara Therapeutics starts first clinical study of oral CR-845

Swissmedic approves Celgene's Revlimid

GLPG-0634 shows signs of efficacy and safety in phase II study

Trimel Pharmaceuticals provides update on CompleoTRT study

EMA committee recommends approval of new indication for Herceptin

Phase III study investigates CXA-201 and metronidazole for intra-abdominal infections

Celgene to discontinue study of treatment regimen for castration-resistant prostate cancer

Landmark study to evaluate regenerative stem cell strategy to treat MS

Milestone reached in PsychoGenics/Roche drug discovery collaboration

FDA accepts for review Regeneron's sBLA for Arcalyst

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...